Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

European Medical Information Framework

EMIF

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information...

Funding Programme
Start Date
End Date
Total Funding
€ 53 642 677

European Quality In Preclinical Data

EQIPD

Pharmaceutical industry, as well as basic science, depend on robust data and scientific rigor as key drivers for decision making, patent strength and time-to-market, which in turn will determine knowledge gain and availability of new treatments to patients. Recent publications report challenges with the robustness, rigor, and/or validity of...

Funding Programme
Start Date
End Date
Total Funding
€ 9 845 484
European Countries Involved

Exploring neuro-glymphatic coupling during sleep using wearable technology

GlymphoSleep

In recent years, it has been demonstrated that sleep not only plays a crucial role in cognitive, emotional, and immunological functions but also helps to clear the brain from metabolic waste products via the recently discovered glymphatic system. A physiological marker closely associated with glymphatic clearance is electroencephalographic (EEG)...

Funding Programme
Start Date
End Date
Total Funding
€ 203 464
European Countries Involved

FLuorescent nanO-agents for super-Resolution Imaging and seNsing

FLORIN

Since Alzheimer disease (AD) affects up to 50% of individuals above 85, we will witness the three-fold increase in the number of patients by 2050 if no efficient therapy will be found. The FLORIN offers non-invasive real-time monitoring of key mechanisms involved in the AD pathogenesis by avant-garde bioimaging at temporal resolution less than 1...

Funding Programme
Start Date
End Date
Total Funding
€ 791 200
European Countries Involved

FROM PATIENT DATA TO PERSONALISED HEALTHCARE IN ALZHEIMER'S DISEASE

PredictAD

Dementia causes long and oppressive suffering to patients and their relatives and imposes enormous costs on society. About 25 million people suffered from dementia in 2000. As a 4-fold increase of this number is expected by 2050, dementia is one main health issue of the next decades. Alzheimer's disease (AD) covers 60-70% of all dementia cases. No...

Funding Programme
Start Date
End Date
Total Funding
€ 3 908 233
European Countries Involved

Generalised EMF Research using Novel Methods – an integrated approach: from research to risk assessment and support to risk management

GERONIMO

The EU population is increasingly exposed to new physical and chemical agents in the environment, some of which may be detrimental to public health. Of these, electromagnetic fields (EMF) are one of the most ubiquitous, with new EMF technologies and novel applications being actively developed and commercialised. To address pertinent questions on...

Funding Programme
Start Date
End Date
Total Funding
€ 7 853 407

Generation of Improved Cellular and Animal Models for Identification of Disease Phenotype and New Therapeutic Targets of Alzheimer’s Disease

MADGIC

The mechanisms of Alzheimer’s disease (AD) have remained poorly understood while com- mon animal models have not helped in finding efficient therapies for the disease. This pro- ject aims to generate new human cellular models allowing for the purification of specific neural cell types involved in AD. We generate patient neural cells through...

Funding Programme
Start Date
End Date
Total Funding
€ 1 901 835
European Countries Involved

Healthy Aging Through Internet Counselling in the Elderly

HATICE

Diabetes mellitus, hypertension, obesity, hypercholesterolemia, smoking and physical inactivity are common in elderly persons and are all associated with an increased risk of myocardial infarction, stroke and dementia. Efficacious treatments of these cardiovascular diseases are available, but in elderly patients with multiple cardiovascular...

Funding Programme
Start Date
End Date
Total Funding
€ 7 423 520
European Countries Involved

Improving health services for European citizens with dementia: Development of best practice strategies for the transition from ambulatory to institutional long-term care facilities

RIGHTTIMEPLACECARE

Given the increasing number of patients/consumers with dementia, political action is urgently required to prepare the health care services throughout Europe to deliver cost effective high quality long-term care to people concerned. Currently there is a lack of clinical research data of patients/consumers and informal caregivers to develop best...

Funding Programme
Start Date
End Date
Total Funding
€ 3 897 650
European Countries Involved

Inflammation and AD: modulating microglia function focussing on TREM2 and CD33

PHAGO

Alzheimer’s disease (AD) is an age-related chronic neurodegenerative disease with four main pathological changes in the brain: amyloid plaques, fibrillary tau tangles, inflammation and neuronal loss. Phagocytes around amyloid plaques in late onset AD (LOAD) may be neurotoxic but have limited motility and phagocytic activity, suggesting a...

Funding Programme
Start Date
End Date
Total Funding
€ 18 088 176

Multimodal preventive trials for Alzheimer’s Disease: towards multinational strategies

MIND-AD

The anticipated pandemic increase in the number of Alzheimer disease (AD) and dementia cases carries serious implications for society. The goal of the MIND-AD project is to identify effective prevention strategies for AD/dementia tailored to different at-risk groups. The project is based on experiences and data from five ongoing European...

Funding Programme
Start Date
End Date
Total Funding
€ 0
European Countries Involved

NAD+ International Scientist-training

NADIS

Nicotinamide adenine dinucleotide (NAD+) is a central redox cofactor and the limiting substrate of key metabolic enzymes. The constellation of cellular functions in which NAD+ is involved makes its availability critical for cell survival, and its depletion is a leading factor in a number of diseases in humans, ranging from rare inherited defects to...

Funding Programme
Start Date
End Date
Total Funding
€ 2 530 832
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).